Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PP 405

Next Previous
Drug Profile

PP 405

Alternative Names: PP-405

Latest Information Update: 23 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles
  • Developer Pelage Pharmaceuticals
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Mitochondrial membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia

Most Recent Events

  • 15 Oct 2025 Adverse events data from a phase IIa trial in Alopecia released by Pelage Pharmaceuticals
  • 15 Oct 2025 Pelage Pharmaceuticals plans a phase III trial for Alopecia, in 2026
  • 01 Oct 2025 Pelage Pharmaceuticals completes a phase II trial in Alopecia in USA (Topical) (NCT06393452)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top